Goa-based Molbio Diagnostics, backed by Temasek and Motilal Oswal Private Equity, has secured Securities and Exchange Board of India’s (SEBI's) approval to raise funds through initial public offering (IPO). The IPO comprises a fresh issue of equity shares aggregating up to Rs 200 crore and an offer-for-sale (OFS) of up to 1.25 crore equity shares by existing shareholders.
The company plans to utilise Rs 99.3 crore from the net proceeds for setting up infrastructure for a new Research and Development facility, a Centre of Excellence and connected office space. Another Rs 73.5 crore will go towards the purchase of plant and machinery for its manufacturing units in Goa and Visakhapatnam, while the balance will be used for general corporate purposes. Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are book-running lead managers to the issue.
Molbio Diagnostics is engaged in point-of-care molecular diagnostics for over 30 diseases, including tuberculosis, COVID-19, HIV, HPV and Hepatitis B & C.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 489.50 |
| Poly Medicure | 1651.20 |
| Laxmi Denta | 214.95 |
| Nureca Ltd. | 289.30 |
| Hemant Surgical Inds | 301.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: